Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
Maximus Berger, Barnaby Nelson, Connie Markulev, Hok Pan Yuen, Miriam R Schafer, Nilufar Mossaheb, Monika Schloegelhofer, Stefan Smesny, Ian B Hickie, Gregor E Berger, Eric YH Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Rossler, Swapna Verma, Andrew Thompson, Alison Ruth Yung, Patrick D McGorry, G Paul Amminger
FRONTIERS IN PSYCHIATRY | FRONTIERS MEDIA SA | Published : 2019
Background: Deficiencies in membrane polyunsaturated fatty acids (PUFA) such as omega-3 (n-3) fatty acids are thought to contribute to the pathophysiological processes underlying psychotic disorders. Emerging evidence suggests that the levels of PUFA are related to clinical symptoms but significant heterogeneity exists between studies. Here, we investigated associations of membrane PUFA with clinical symptoms and functioning in a large sample of individuals at ultra-high risk (UHR) for psychosis. Methods: A total of 285 participants of the NEURAPRO clinical trial were investigated for erythrocyte PUFA levels, including the n-3 index, n-6/n-3 PUFA ratio, docosahexaenoic acid (DHA), and eicosa..View full abstract
Awarded by Stanley Medical Research Institute
Awarded by NHMRC Australia
Awarded by Swiss National Science Foundation
The NEURAPRO clinical trial was supported by grant 07TGF-1102 from the Stanley Medical Research Institute, grant 566529 from the NHMRC Australia, and a grant from the Colonial Foundation. The analysis of fatty acids was supported by grant 1128631 from the NHMRC Australia. MB is supported by a MACH Translational Research Fellowship. GB is supported by the Swiss National Science Foundation (SNF 33IC30_166826).